Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

Swine Flu Media Bulletin Issued At: 11am Monday 18 May 2009, Wales
-- 0 confirmed cases in Wales.
generic viagra online
Utah Bill Would Offer Parents Choice Of Two Sex Education Options
A bill (H.B. 189) before the Utah Legislature"s Health and Human Services Interim Committee would allow parents to choose between two sex education curriculums, the Salt Lake City Deseret News reports. The first curriculum would be "abstinence-based and teach strategies for waiting until marriage but also offer information about issues such as sexually transmitted" infections. The "other class would emphasize abstinence but also offer facts," including STI prevention and contraceptive options.State Rep. Lynn Hemingway (D), who proposed the bill, cited data from the state Department of Health showing that 4,356 young women became pregnant in 2007 and that there were 1,805 reported cases of chlamydia among girls ages 15 to 19 in 2008, an increase from 1,332 in 2005. Hemingway said, "These numbers are frightening. This isn"t a moral issue anymore. This is a health issue." Hemingway"s bill is modeled after similar legislation under consideration in North Carolina.According to the Deseret News, the state Office of Education"s rule on sex education currently states that educators are allowed to instruct on contraception options if they have parental consent. Some advocates, policymakers and teens argue that students are receiving inadequate sex education because instructors are leaving out important information over concern that they will be accused of advocating sex. Hemingway"s bill allows instructors to provide information on contraception "without fear of reprimand," according to the Desert News (Stewart, Salt Lake City Deseret News, 6/18).
News of the day
Babies Born To Native High-Altitude Mothers Have Decreased Risk Of Low Birth Weight
Pregnant women who are indigenous to the Andes Mountains deliver more blood and oxygen to their fetuses at high altitude than do women of European descent. The study helps explain why babies of Andean descent born at high altitude weigh more than European babies born at altitude.
Diagnostics

FDA Accepts CyDex Pharmaceuticals' IND Application For Oncology Drug

CyDex Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company"s Investigational New Drug (IND) application for a clinical study of Captisol-Enabled® melphalan HCL (CDX-353). Melphalan is an FDA-approved low dose chemotherapy for multiple myeloma marketed under the brand name Alkeran® by GlaxoSmithKline. In December 2008, CyDex received orphan-drug designation from the FDA for melphalan "as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation." This designation provides an important economic incentive, granting CyDex seven years of exclusive marketing rights. "IND acceptance for Captisol-enabled melphalan is an important milestone for CyDex as we work to develop a portfolio of new drugs for the hospital acute care market," said Theron E. Odlaug, CyDex"s president and chief executive officer. "We look forward to establishing a relationship with a strategic out-licensing partner to advance CDX-353 into the clinic and, longer-term, develop and commercialize this promising oncology product." Upcoming clinical studies are expected to begin with a phase 2(a) trial that compares the pharmacokinetics of CyDex"s CDX-353: Propylene Glycol-Free Melphalan HCL with Alkeran, and evaluate safety parameters. Alkeran is packaged as two separate vials that must be combined prior to injection and, due to its limited stability, administered immediately thereafter. CyDex"s version of melphalan is enabled by Captisol®, the company"s proprietary and patented sulfobutylether í²-cyclodextrin. Captisol-Enabled® melphalan is a one-vial formulation that does not contain harsh co-solvents and remains stable at room temperature for an extended period of time. "CDX-353 is a novel form of melphalan that is more stable and could potentially allow for longer administration durations and slower infusion rates compared to current pre-transplant treatments for multiple myeloma," said Parameswaran Hari, M.D., Clinical Director of the Adult Bone Marrow Transplant Program and Associate Professor of Medicine at the Medical College of Wisconsin. "These advantages have the potential to enable doctors to safely achieve a higher dose intensity of pre-transplant chemotherapy, which could lead to better therapeutic outcomes." CyDex Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009